Micron's Q4 and full-year results delivered record revenues, with DRAM for AI as the primary growth engine. Click here to find out why MU stock is a Buy.

Hanmi Pharmaceutical has applied for Phase 1 clinical trials to commercialize a "novel obesity drug" that, for the first time in the world, achieves ...

Researchers at Stockholm University and Karolinska Institutet have found a system in the brain that can explain why female mice, who are not normally aggressive, suddenly and dramatically gain access ...

Akkermansia muciniphila is an emerging “next-generation” probiotic with data supporting improvements in intestinal integrity, metabolic markers, and immune modulation. This article reviews potential ...